Taysha Gene Therapies, Inc.
TSHA
Výsledovka
Rozvaha
Peněžní toky
Ukazatele
Klíčové metriky
V miliónech (USD)
| Operating Income | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 56.8 | 91.2 | 131.9 | 31.9 | |
| Selling General & Admin Expenses | 0.0 | 0.0 | 30.0 | 37.4 | 41.3 | 11.1 | |
| Depreciation & Amortization | 1.2 | 1.2 | 1.4 | 36.7 | 0.2 | -17.0 | |
| Total Operating Expenses | 108.2 | 99.8 | 87.9 | 128.5 | 173.3 | 43.0 | |
| Operating Income | -102.1 | -91.5 | -72.4 | -162.4 | -173.3 | -43.0 | |
| Net Income | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
| Interest Income | 8.1 | 6.9 | 3.6 | 0.2 | 0.2 | 0.0 | |
| Interest Expense | 0.1 | 0.1 | 5.0 | 3.8 | 1.4 | 0.0 | |
| Other Expense | 2.2 | 2.2 | -39.1 | -3.6 | -1.3 | -17.0 | |
| IBT | -99.9 | -89.3 | -111.6 | -166.0 | -174.5 | -60.0 | |
| Income Tax Expense | 0.0 | 0.0 | 0.0 | 3.6 | 0.9 | -17.0 | |
| Net Income | -99.9 | -89.3 | -111.6 | -169.6 | -175.5 | -43.0 | |
| Per Share Data | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $-0.96 | $-3.86 | $-4.66 | $-2.43 | |
| EPS Diluted | $0.00 | $0.00 | $-0.96 | $-3.86 | $-4.66 | $-2.43 | |
| Shares Outstanding | 353.3 | 250.1 | 116.1 | 44.0 | 37.7 | 17.7 | |
| Diluted Shares Outstanding | 353.3 | 250.1 | 116.1 | 44.0 | 37.7 | 17.7 | |
| Cash Flow From Operating Activities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
| Net Income | -114.3 | -89.3 | -111.6 | -166.0 | -174.5 | -60.0 | |
| Depreciation & Amortization | 1.3 | 1.2 | 1.4 | 1.2 | 0.5 | 0.0 | |
| Stock-Based Compensation | 10.5 | 13.1 | 7.9 | 18.0 | 18.2 | 3.4 | |
| Change Working Capital | -16.2 | -12.5 | -18.0 | 18.5 | 28.7 | -0.1 | |
| Change In Accounts Receivable | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Change In Accounts Payable | -2.1 | -2.9 | -2.3 | -7.8 | 14.5 | 2.0 | |
| Change In Inventories | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Non-cash Items | -48.4 | 6.2 | 47.3 | 39.9 | 10.1 | 26.0 | |
| Cash from Operations | -75.4 | 0.0 | -73.0 | -88.4 | -117.0 | -30.7 | |
| Cash Flow From Investing Activities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
| Capital Expenditure | -3.9 | -0.4 | -3.9 | -24.9 | -21.6 | -9.1 | |
| Acquisitions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Sales of Investment | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Investing Activities | 0.0 | 0.0 | -3.5 | -0.1 | 0.0 | 0.0 | |
| Cash from Investing | -3.8 | 0.0 | -7.4 | -24.9 | -21.6 | -9.1 | |
| Cash Flow From Financing Activities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
| Debt Repaid | -3.8 | 0.0 | -3.5 | 0.0 | 0.0 | -1.7 | |
| Debt Issued | 2.1 | 2.1 | 4.6 | -3.2 | 63.1 | 1.7 | |
| Issuance of Common Stock | 211.3 | 0.0 | 140.8 | 53.2 | 0.0 | 165.9 | |
| Repurchase of Common Stock | -0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | -0.6 | 0.0 | -0.6 | -1.1 | 39.1 | 126.9 | |
| Cash from Financing | 206.9 | 0.0 | 136.4 | 52.1 | 39.1 | 291.1 | |
| Cash position | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
| Net Change in Cash | 128.1 | -4.9 | 56.0 | -61.2 | -99.5 | 251.3 | |
| Closing Cash Balance | 173.2 | 141.6 | 146.5 | 90.5 | 151.7 | 251.3 | |
| Free Cash Flow | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
| Free Cash Flow | -79.2 | -81.6 | -80.4 | -113.3 | -138.6 | -39.8 | |
| Real Free Cash Flow | -89.8 | -94.7 | -88.3 | -131.3 | -156.8 | -43.2 | |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
